The Price Is the Strategy: What Nineteen Launches Taught Me About Pricing in Life Sciences
This is the third post in a five-part series — What 19 Product Launches Taught Me.
Post 2 — segmentation, targeting, positioning
Most organizations treat pricing as the last commercial decision. They believe the market will tell them what the product is worth — that adoption data, competitive benchmarking, and payer feedback will calibrate the price to whatever the market will bear. And the market will tell them. What it reports is perceived value. Not true economic value. The gap between the two is where pricing strategy lives — and where most commercial organizations leave significant value on the table.
Price is the variable consumers consider more than any other. It is the most sensitive element of the commercial mix — more immediately processed than messaging, more directly connected to the purchase decision than any positioning claim. A small change in price can move volume by magnitudes that no other marketing variable can match. And in life sciences, where the channel economics of US healthcare add layers of complexity that most pricing frameworks do not account for, getting it wrong — in either direction — produces consequences that compound across the product's commercial life.
Nineteen product launches across five therapy sectors taught a consistent lesson about pricing: the organizations that built their pricing strategy around a rigorous understanding of what the product was actually worth — to a fully informed customer, relative to every available alternative — consistently captured more value and sustained commercial momentum longer than the organizations that priced to the market average or to the competitor's list price.
The market reports perceived value. Pricing strategy is the discipline of understanding the gap between perceived value and true economic value — and deciding how to close it.
The Three-Factor Framework: TEV, Perceived Value, and COGS
Value-based pricing rests on a three-factor framework that determines where the price should sit, why it should sit there, and what the commercial consequences are of placing it anywhere else.
True Economic Value (TEV) is the total value a fully informed customer would ascribe to the product — the objective measure of the benefit the product delivers relative to every available alternative. TEV is calculated by starting with the cost of the next best alternative and adding the monetary value of every incremental benefit the product provides: time savings, decreased resource consumption, reduced downstream costs, better outcomes, fewer adverse events. In life sciences, TEV frequently far exceeds the price at which the product is sold — because demonstrating TEV to a payer, a physician, or a health system requires the kind of health economics evidence that most organizations begin building too late.
Perceived Value is the consumer's maximum willingness to pay — the value the customer understands and believes the product delivers based on the information available to them. Perceived value is almost always lower than TEV, because the full benefit of a product is rarely observable at the point of purchase. The physician who has not yet seen outcomes data in their own patient population perceives less value than the physician who has. The payer who has not reviewed the health economics model perceives less value than the payer who has. Closing the gap between perceived value and TEV is the core function of medical affairs, health economics, and outcomes research — not marketing communications. Marketing communicates the claim. Medical affairs and HEOR substantiate it.
Cost of Goods Sold (COGS) is the fully accounted variable cost of producing the product. A price set between perceived value and COGS creates an incentive for the customer to purchase and an incentive for the organization to sell. A price set above perceived value — regardless of its relationship to TEV — creates adoption resistance that compounds over time into a market access problem. A price set below COGS is not a pricing strategy. It is a path to insolvency.
Value-based pricing decision: price between perceived value and COGS, close enough to perceived value to create a customer incentive to purchase, and above COGS to create an organizational incentive to sell. The gap between the price and perceived value is the customer's value capture. The gap between the price and COGS is the organization's value capture.
The Five Pricing Strategies — and When Each Is Appropriate
Pricing strategy is not a choice made once. It is a decision informed by the competitive landscape, the product's IP position, the segment's price sensitivity, the organization's cost structure, and the lifecycle stage of the market. Five strategies cover the range of conditions that life sciences organizations encounter:
1. Skim Pricing — sets a high initial price to capture maximum value from the least price-sensitive customers before lowering the price to reach broader segments. Appropriate when IP protection limits competitive entry, target segments are identifiable and reachable, and each segment has a meaningfully different perception of value. The risk: if the IP position erodes faster than anticipated, skim pricing creates a window in which a competitor can enter below the skim price and capture market share before the organization can respond.
2. Penetration Pricing — sets a low initial price to maximize market share quickly, building the scale and learning economies that lower unit costs over time and create competitive barriers that make the market less attractive for new entrants. Appropriate when customers are price sensitive, scale economies are achievable, and the organization's cost structure can sustain the lower price until volume compensates. The risk: penetration pricing is difficult to reverse — raising prices on a customer base that adopted the product at a lower price creates resistance that promotion cannot easily overcome.
3. Price Customization — offers the same product at different prices to different customer segments — economists call this third-degree price discrimination. Appropriate when segments have meaningfully different willingness to pay, the organization has the customer information to identify which segment each buyer occupies, there are no grey markets through which lower-price customers can resell to higher-price segments, and the pricing difference does not generate customer ill will that outweighs the revenue gain. In life sciences, price customization is standard practice across geography, payer type, and channel — US list price versus net price versus international price are all expressions of price customization.
4. Price Bundling — sets a price for a combination of products that is different from the sum of individual prices — offering customers with different willingness to pay for different products an incentive to purchase both. Appropriate when the organization sells multiple products with genuine commercial synergy, and when customers in different segments have meaningfully different preferences across the product set. In diagnostics and device portfolios, bundling is a structural commercial advantage that individual product pricing cannot replicate.
5. Competitive Pricing — sets prices at the market average — appropriate when the market is mature, products are genuinely similar, and prices have moved toward an equilibrium over time. Competitive pricing is a reasonable default for commodity markets. It is not a strategy for products that have a genuine point of differentiation — because a product priced at the market average communicates to the customer that it is worth the market average, regardless of what the medical affairs team has demonstrated about its TEV.
What Makes Customers Price Sensitive — and Why It Matters
Price sensitivity is not a fixed characteristic of a customer or a market. It is a variable that shifts with the conditions under which the purchase decision is made. Understanding what drives price sensitivity in a given segment and a given competitive context is a commercial intelligence asset — because an organization that can reduce price sensitivity without reducing price captures more value from the same commercial investment.
Low performance differentiation — makes price the only differentiating factor. When customers perceive little meaningful difference between competing products, they default to price as the decision criterion. The commercial implication: if the organization cannot establish a credible point of differentiation in the customer's mind, the pricing conversation will be dominated by the competitor's price, not the product's value.
Comparability at point of purchase — increases sensitivity. When two comparable products are visible side by side — on a formulary, in a competitive analysis, in a payer review — the customer's attention moves to the price difference. Organizations that can reduce direct comparability — through differentiated positioning, through access restrictions, through channel strategy — reduce the conditions under which price sensitivity is highest.
Price as a signal of quality — reduces sensitivity. When price reliably signals value — when customers have learned through experience that higher-priced products in a category produce better outcomes — premium pricing reinforces the positioning claim rather than creating adoption resistance. In life sciences categories where outcome differences are observable and attributable, this relationship holds. In categories where outcome differences are difficult to observe or attribute, it does not.
Pain of payment — increases sensitivity when the decision-maker bears the cost directly. In business-to-business life sciences contexts — hospital formulary committees, pharmacy and therapeutics committees, integrated delivery network purchasing — the deliberative, committee-based decision-making process ensures that price sensitivity is higher than in direct-to-prescriber contexts. The commercial implication: the value proposition presented to the formulary committee must be grounded in health economics, not clinical evidence alone.
The US Healthcare Channel: Where Pricing Gets Complicated
Pricing in life sciences does not occur in a vacuum. The US healthcare system's channel architecture means that the list price a manufacturer sets is not the price any participant in the channel actually pays — and the gap between list price and net price varies by product category, channel pathway, payer mix, and contracting strategy in ways that fundamentally shape the commercial model.
Three channel pathways create three distinct pricing environments:
Buy-and-bill is the model in which a physician or hospital purchases the product directly, administers it to the patient, and bills the payer for both the product and the administration. The physician or hospital bears the acquisition cost and the reimbursement risk. The pricing discipline here is gross-to-net management — the relationship between the list price billed to the payer and the net price after rebates, discounts, and chargebacks. Favorable reimbursement rates and formulary placement are commercial assets as important as any promotional investment.
Specialty pharmacy distribution moves the product through a pharmacy benefit rather than a medical benefit, with the patient as the point of dispensing. Payer contracting, prior authorization requirements, step therapy protocols, and specialty pharmacy network design all affect whether the patient who has been prescribed the product actually receives it. The commercial implication: pull-through strategy — ensuring that prescriptions written are prescriptions filled — is a distinct commercial challenge from generating the prescription in the first place.
Laboratory and diagnostic channels operate under a professional fee model in which the payer reimburses the laboratory for performing the test rather than the manufacturer for supplying the reagent or platform. Reimbursement codes, coverage determinations, and medical policy are the commercial levers — and the relationship between the manufacturer and the payer is mediated by the laboratory's billing infrastructure rather than by a direct contracting relationship.
Across all three pathways, the complexity of managed care — formulary tiers, prior authorization hurdles, step therapy requirements, utilization management programs — means that market access strategy is not a post-approval function. It is a commercial strategy function that must be integrated into pricing, positioning, and the evidence generation plan from the earliest development stages. The organization that arrives at approval without a market access architecture built around its pricing strategy will spend the first years of commercial life correcting a problem it could have prevented.
The list price is the beginning of the pricing conversation in US healthcare, not the end. The net price — after every layer of the channel takes its margin and every payer extracts its rebate — is what the commercial model must be built around.
Price Is the Strategy
The fastest and most effective way for a life sciences organization to realize its maximum profit is to get its pricing right. Not approximately right — precisely right, calibrated to the TEV the product delivers, the perceived value the customer currently holds, and the channel economics of the distribution pathway through which the product reaches the patient.
Getting it right requires treating pricing not as the last decision — the number the finance team assigns after the commercial strategy is built — but as a strategic input that shapes the evidence generation plan, the market access architecture, the positioning strategy, and the communication investment. A product positioned as premium cannot be priced at parity without undermining the positioning claim. A product priced for penetration cannot sustain a skim strategy when IP protection erodes without destroying the customer relationships built at the lower price.
What nineteen launches taught is that pricing decisions made early — made with a rigorous understanding of TEV, perceived value, segment willingness to pay, and channel economics — compound commercial advantage in ways that pricing decisions made late cannot recover. The market will tell the organization what it has priced its product at. The organization's job is to decide what the product is actually worth — and then build the commercial evidence to close the gap between what the market perceives and what the product delivers.
The market will tell you what it perceives your product is worth. Your job is to know what it is actually worth — and build the commercial evidence to close the gap.
In This Series
Post 1: What 19 Product Launches Taught Me: A Field Guide to Commercial Viability
Post 2: Know Your Customer Better Than They Know Themselves
Post 3: The Price Is the Strategy — You are here.
